Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 437 participants.

Also called NCT05990205

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 437 participants (enrolled count) (from the registry)
Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (from the registry)
Registry
  • NCT NCT05990205
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05990205. Randomized; no masking; primary purpose prevention. Start 2018-04-17 (actual); primary completion 2023-12-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes
Acronym
PRED2
Condition
PreDiabetes
Intervention (Drug)
Life Style Intervention + Metformin
Intervention (Behavioral)
Life Style Intervention
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (class: other)

Record details

Record id
cardio:ct-nct05990205
Content hash
cf8c980e1629a64d0ef8a37d1c58a9dc17ec93e595477752410b4aa21ddfe397